3 results
Approved WMOCompleted
The aim of this study is to assess the safety and tolerability of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis.
Approved WMORecruiting
The main objective of PD0053 is to provide POC for the efficacy of the ASYN misfolding inhibitor UCB0599 in reducing disease progression in study participants with early-stage PD, and to instruct later stage development. The ultimate goal is to…
Approved WMOCompleted
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF.